A Phase I Study of ZD6474 (Zactima) Alone and in Combination with Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma and Medulloblastoma.

Trial Profile

A Phase I Study of ZD6474 (Zactima) Alone and in Combination with Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma and Medulloblastoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2011

At a glance

  • Drugs Tretinoin; Vandetanib
  • Indications Medulloblastoma; Neuroblastoma
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 14 Nov 2011 Actual patient number is 10 according to ClinicalTrials.gov.
    • 14 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top